Skip to content

Study · Randomized controlled trial · 2001

3 results

Effect of endocrine treatment on sexuality in premenopausal breast cancer patients: a prospective randomized study.

Berglund G, Nystedt M, Bolund C, Sjödén PO, Rutquist LE

Journal of clinical oncology : official journal of the American Society of Clinical Oncology1 Jun 2001Cited by 113 (Europe PMC)

PMID11387349 (opens in a new tab)DOI10.1200/jco.2001.19.11.2788 (opens in a new tab)PepBankPUB-11387349
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    In premenopausal breast cancer patients without chemotherapy, Zoladex increased sexual dysfunction versus no endocrine treatment from 1 to 2 years.

    In plain wordsIn breast cancer patients without chemotherapy, Zoladex increased sexual dysfunction versus no endocrine treatment from 1 to 2 years.

    Peptide
    Goserelin
    Outcome
    IncreaseSexual dysfunction without chemotherapy
    Study

    n: not reported in source

    Comparator
    no endocrine treatment
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    Dose not stated · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    In contrast, among patients who did not receive chemotherapy, Zoladex and ZT produced a significantly higher level of dysfunction from 1 to 2 years after inclusion, as compared with those who received no endocrine treatment.
    1 context sentence
    Summary · context
    This prospective study examined several aspects of sexuality through the use of self-administered questionnaires, which were completed by patients at seven points of assessment for 3 years after randomization.
  2. 02HumanNon-randomized trialSafety outcome

    In premenopausal breast cancer patients, Zoladex had a negative effect on sexual fear.

    In plain wordsIn premenopausal breast cancer patients, Zoladex worsened sexual fear.

    Peptide
    Goserelin
    Outcome
    IncreaseSexual fear
    Study

    n: not reported in source

    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    Dose not stated · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    Zoladex had a negative effect on sexual fear, which was reduced by the addition of tamoxifen.
    1 context sentence
    Summary · context
    This prospective study examined several aspects of sexuality through the use of self-administered questionnaires, which were completed by patients at seven points of assessment for 3 years after randomization.
  3. 03HumanNon-randomized trialSafety outcome

    In premenopausal breast cancer patients without chemotherapy, sexual dysfunction during goserelin treatment was reversible after treatment ended.

    In plain wordsIn premenopausal breast cancer patients without chemotherapy, sexual dysfunction during goserelin treatment was reversible after treatment ended.

    Peptide
    Goserelin
    Outcome
    DecreaseReversibility of sexual dysfunction
    Study

    n: not reported in source

    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    Dose not stated · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    Zoladex increased sexual dysfunction during treatment among patients without chemotherapy, but the disturbances of sexual functioning were reversible.
    2 context sentences
    Summary · context
    After termination of endocrine treatment, sexual dysfunction began to diminish.
    Summary · context
    This prospective study examined several aspects of sexuality through the use of self-administered questionnaires, which were completed by patients at seven points of assessment for 3 years after randomization.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.